Pfizer has removed sitaxentan from the market after concerns were raised about liver toxicity associated with the treatment.
The pharmaceutical firm has recommended that no new patients are prescribed sitaxentan and that patients already on the medicine should contact their doctors.
Pfizer said that although liver toxicity is a known side-effect of the endothelin-receptor antagonists, they had observed a new, idiosyncratic and potentially life-threatening reaction to sitaxentan.
Copyright © Press Association 2011
You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?